Where does Scinopharm Taiwan Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Scinopharm Taiwan Ltd. ranks #9,117 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Scinopharm Taiwan Ltd. hold?

Scinopharm Taiwan Ltd. holds 35 US utility patents granted between 2015 and 2025, spanning 14 technology areas.

What is Scinopharm Taiwan Ltd.'s Innovation Score?

Scinopharm Taiwan Ltd. has an Innovation Score of 40.5 out of 100 (top 35% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Scinopharm Taiwan Ltd. focus on?

Scinopharm Taiwan Ltd.'s top technology area is C07D (Heterocyclic Compounds) with 21 patents, ranking #419 of 3,165 assignees active in that subclass. Grants appear in 14 CPC subclasses total.

Is Scinopharm Taiwan Ltd.'s patent grant rate increasing or decreasing?

Scinopharm Taiwan Ltd.'s recent grant velocity is -78% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Scinopharm Taiwan Ltd.'s patents?

Scinopharm Taiwan Ltd.'s patents average 15.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Scinopharm Taiwan Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Scinopharm Taiwan Ltd.

USPTO PatentsView assignee record - 35 granted patents across 14 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Scinopharm ranks #9,117 of 49,997 tracked US assignees by granted-patent volume, with 35 patents across 14 technology areas.

#9,117
of 49,997 US assignees by volume: Top 35%
by Innovation Score (40.5/100): 15.9
avg claims per patent: -78%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9117 · Foreign Corporation #9,117 · 35 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 35 grants
UPPER-Q #9,117/49,997
PHOTO-FINISH Robert Welch Designs
CPC-FOCUS C07D · 14 areas
INNOV-PAR 40.5/100
CLAIMS-RICH 15.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -78% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Robert Welch Designs Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Scinopharm’s 40.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.4 pts (31%) Velocity 5.3 pts (13%) Breadth 13.2 pts (33%) Claim depth 9.5 pts (24%)

Qualcomm Incorporated · highest

85
Montage Technology… · near

40
Rambus Delaware · near

40
Rolling Razor · near

40
Scinopharm Taiwan · this assignee

40
SKF Lubrication… · near

40
3D Lighting… · lowest

7

What this shows Scinopharm's Innovation Score is 40.5/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Scinopharm?

Each dot is one of Scinopharm’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Scinopharm’s own 15.9 claims/patent is ABOVE the 12.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Scinopharm vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Scinopharm's grants concentrate

Scinopharm Taiwan Ltd. is a focused PatentsView assignee: 14 CPC subclasses with 60% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (9 grants) versus a trough of 1 in 2020. By volume, Scinopharm sits between Robert Welch Designs Ltd. and Sito Mobile R&D IP, LLC.

Scinopharm's three-year grant acceleration

Scinopharm Taiwan Ltd. shows 4 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Robert Welch Desi…

35
Robotic Research…

35
S I P A Societa'…

35
Sanofi Biotechnol…

35
Seikoh Giken

35
Shannon Systems

35
Showa Glove

35
Sito Mobile R&D IP

35
Scinopharm Taiwan ◀

35

What this shows Scinopharm holds 35 patents at rank #9,115, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Scinopharm

By rank, the assignees closest to #9,115 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Scinopharm's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Scinopharm, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Scinopharm ranks #419 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

SKF Lubrication Systems Germany GMBH 40 Montage Technology (SHANGHAI) Co., Ltd. 40 Rambus Delaware LLC 40 Rolling Razor, Inc 40

Scinopharm's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 35% higher than 65% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Scinopharm Taiwan Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	14.3%
2016	5	14.3%
2017	9	25.7%
2018	5	14.3%
2019	3	8.6%
2020	1	2.9%
2021	1	2.9%
2022	3	8.6%
2023	1	2.9%
2025partial year	2	5.7%

Which technologies does Scinopharm Taiwan Ltd. patent most?

C07D - Heterocyclic Compounds 21

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 9

C07K - Peptides 4

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 3

C07C - Acyclic OR Carbocyclic Compounds 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C08B - POLYSACCHARIDES; Derivatives Thereof 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

C07J - Steroids 1

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

Y10T - Technical Subjects Covered BY Former US Classification 1

Top 14 of 14 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Scinopharm Taiwan Ltd.'s patent record in context - here's where to go next.

Scinopharm Taiwan Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 60% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #9,117 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Scinopharm Taiwan Ltd. against Robert Welch Designs Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.